MLH1 negative
|
endometrial cancer
|
sensitive
|
Dostarlimab-gxly
|
Guideline |
Actionable |
Jemperli (dostarlimab-gxly) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
35690222
detail...
|
CD274 positive
|
gastroesophageal junction adenocarcinoma
|
sensitive
|
Nivolumab
|
Guideline |
Actionable |
Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated gastroesophageal junction adenocacinoma expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org).
|
detail...
35914639
|
RET fusion
|
lung non-small cell carcinoma
|
sensitive
|
Selpercatinib
|
Guideline |
Actionable |
Retevmo (selpercatinib) is included in guidelines as a first-line therapy for patients with metastatic non-small cell lung cancer harboring RET fusions (PMID: 36872130; ESMO.org).
|
36872130
detail...
|
ALK rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Ceritinib
|
Guideline |
Actionable |
Zykadia (ceritinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring an ALK rearrangement (PMID: 30285222; ESMO.org).
|
detail...
30285222
|
PMS2 negative
|
endometrial cancer
|
sensitive
|
Avelumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Bavencio (avelumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
36696825
detail...
|
TP53 mutant
|
chronic lymphocytic leukemia
|
sensitive
|
Idelalisib + Rituximab
|
Guideline |
Actionable |
Zydelig (idelalisib) and Rituxan (rituximab) combination therapy is included in the guidelines as first-line therapy for patients with advanced chronic lymphocytic leukemia harboring TP53 mutations and for patients with relapsed or refractory disease (PMID: 33091559; ESMO.org).
|
detail...
33091559
|
FGFR2 fusion
|
cholangiocarcinoma
|
sensitive
|
Futibatinib
|
Guideline |
Actionable |
Lytgobi (futibatinib) is included in guidelines as second or later-line therapy for patients with cholangiocarcinoma harboring FGFR2 fusions (PMID: 36372281; ESMO.org).
|
36372281
detail...
|
MSH2 negative
|
endometrial cancer
|
sensitive
|
Dostarlimab-gxly
|
Guideline |
Actionable |
Jemperli (dostarlimab-gxly) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or advanced endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
36696825
detail...
|
PMS2 negative
|
stomach cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with advanced or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) gastric cancer (PMID: 35914639; ESMO.org).
|
35914639
detail...
|
MSH6 negative
|
colorectal cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with advanced or metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 37236086; ESMO.org).
|
detail...
37236086
|
MSH2 negative
|
endometrial cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
PMS2 negative
|
colorectal cancer
|
sensitive
|
Ipilimumab + Nivolumab
|
Guideline |
Actionable |
Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in guidelines as second-line therapy for patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
ALK rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Crizotinib
|
Guideline |
Actionable |
Xalkori (crizotinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring an ALK rearrangement, or as a next-line therapy in patients with ALK-rearranged non-small cell lung cancer who have not received prior Xalkori (crizotinib) (PMID: 30285222; ESMO.org).
|
30285222
detail...
|
MSH2 negative
|
endometrial cancer
|
sensitive
|
Durvalumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
36696825
detail...
|
MSH2 negative
|
stomach cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with advanced or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) gastric cancer (PMID: 35914639; ESMO.org).
|
35914639
detail...
|
RET mutant
|
thyroid gland medullary carcinoma
|
sensitive
|
Pralsetinib
|
Guideline |
Actionable |
Gavreto (pralsetinib) is included in guidelines for adult or pediatric patients 12 years or older with advanced or metastatic medullary thyroid gland carcinoma harboring RET mutations (PMID: 31549998, PMID: 35491008; ESMO.org).
|
31549998
detail...
35491008
|
NRAS exon2
|
colorectal cancer
|
resistant
|
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in metastatic colorectal cancer patients with NRAS exon 2 mutations (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
FLT3 exon22
|
acute myeloid leukemia
|
sensitive
|
Gilteritinib
|
Guideline |
Actionable |
Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
PMS2 negative
|
endometrial cancer
|
sensitive
|
Durvalumab
|
Guideline |
Actionable |
Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
detail...
35690222
|
FGFR2 fusion
|
bladder urothelial carcinoma
|
sensitive
|
Erdafitinib
|
Guideline |
Actionable |
Balversa (erdafitinib) is included in guidelines for patients with advanced or metastatic bladder urothelial carcinoma harboring FGFR alterations (PMID: 34861372; ESMO.org).
|
detail...
34861372
|
MSH6 negative
|
endometrial cancer
|
sensitive
|
Dostarlimab-gxly
|
Guideline |
Actionable |
Jemperli (dostarlimab-gxly) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or advanced endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
36696825
detail...
|
BRAF V600E
|
colorectal cancer
|
sensitive
|
Cetuximab + Encorafenib
|
Guideline |
Actionable |
Braftovi (encorafenib) in combination with Erbitux (cetuximab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as a second- or subsequent-line therapy for patients with advanced or metastatic colorectal cancer harboring BRAF V600E (PMID: 37236086; ESMO.org).
|
detail...
37236086
|
BRAF V600E
|
colorectal cancer
|
resistant
|
Cetuximab
|
Guideline |
Actionable |
Erbitux (cetuximab), as a monotherapy, is not indicated for use in metastatic colorectal cancer patients with BRAF V600E (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
MSH6 negative
|
colorectal cancer
|
sensitive
|
Ipilimumab + Nivolumab
|
Guideline |
Actionable |
Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in guidelines as second-line therapy for patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
MSH2 negative
|
endometrial cancer
|
sensitive
|
Avelumab
|
Guideline |
Actionable |
Bavencio (avelumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
35690222
detail...
|
FLT3 exon19
|
acute myeloid leukemia
|
sensitive
|
Gilteritinib
|
Guideline |
Actionable |
Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
ALK rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Lorlatinib
|
Guideline |
Actionable |
Lorbrena (lorlatinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring an ALK rearrangement who have progressed on an ALK tyrosine kinase inhibitor (PMID: 30285222; ESMO.org).
|
30285222
detail...
|
RET fusion
|
lung non-small cell carcinoma
|
sensitive
|
Pralsetinib
|
Guideline |
Actionable |
Gavreto (pralsetinib) is included in guidelines as a first-line therapy for patients with metastatic non-small cell lung cancer harboring RET fusions (PMID: 36872130; ESMO.org).
|
detail...
36872130
|
FLT3 exon14
|
acute myeloid leukemia
|
sensitive
|
Gilteritinib
|
Guideline |
Actionable |
Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
detail...
32171751
|
CD274 positive
|
esophagus squamous cell carcinoma
|
sensitive
|
Ipilimumab + Nivolumab
|
Guideline |
Actionable |
Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, TPS>=1%) (PMID: 35914638; ESMO.org).
|
35914638
detail...
|
TP53 mutant
|
chronic lymphocytic leukemia
|
sensitive
|
Ibrutinib
|
Guideline |
Actionable |
Imbruvica (ibrutinib) is included in the guidelines as first-line therapy for patients with advanced chronic lymphocytic leukemia harboring TP53 mutations and for patients with relapsed or refractory disease (PMID: 33091559; ESMO.org).
|
33091559
detail...
|
KIT exon9
|
gastrointestinal stromal tumor
|
sensitive
|
Sunitinib
|
Guideline |
Actionable |
Sutent (sunitinib) is included in guidelines as second-line or subsequent therapy for locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) patients harboring sensitizing mutations, such as KIT exon 9 mutations (PMID: 34560242; ESMO.org).
|
detail...
34560242
|
PMS2 negative
|
cholangiocarcinoma
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second or late-line therapy for patients with cholangiocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36372281; ESMO.org).
|
36372281
detail...
|
ROS1 rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Ceritinib
|
Guideline |
Actionable |
Zykadia (ceritinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring a ROS1 rearrangement who have not received prior Xalkori (crizotinib) therapy (PMID: 30285222; ESMO.org).
|
30285222
detail...
|
MSH2 negative
|
cholangiocarcinoma
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second or late-line therapy for patients with cholangiocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36372281; ESMO.org).
|
detail...
36372281
|
FLT3 exon21
|
acute myeloid leukemia
|
sensitive
|
Cytarabine + Daunorubicin + Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines as first-line treatment for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
ALK rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Brigatinib
|
Guideline |
Actionable |
Alunbrig (brigatinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) as subsequent therapy for patients who have progressed on second-generation ALK inhibitors (PMID: 30596843; ESMO.org).
|
30596843
detail...
|
FLT3 exon16
|
acute myeloid leukemia
|
sensitive
|
Gilteritinib
|
Guideline |
Actionable |
Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
KIT exon9
|
gastrointestinal stromal tumor
|
predicted - sensitive
|
Ripretinib
|
Guideline |
Actionable |
Qinlock (ripretinib) is included in guidelines as fourth-line or subsequent therapy for locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) patients harboring sensitizing mutations, such as KIT exon 9 mutations (PMID: 34560242; ESMO.org).
|
34560242
detail...
|
BRAF V600X
|
skin melanoma
|
sensitive
|
Binimetinib + Encorafenib
|
Guideline |
Actionable |
BRAF inhibitor plus MEK inhibitor combination therapy, such as Mektovi (binimetinib) plus Braftovi (encorafenib), is included in guidelines for cutaneous melanoma patients with unresectable or metastatic disease harboring a BRAF V600 mutation (PMID: 31566661; ESMO.org).
|
31566661
detail...
|
FLT3 exon16
|
acute myeloid leukemia
|
sensitive
|
Cytarabine + Daunorubicin + Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines as first-line treatment for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
CD274 positive
|
esophagus adenocarcinoma
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with advanced or metastatic esophageal adenocarcinoma expressing PD-L1 (CD274, CPS>=10) (PMID: 35914639; ESMO.org).
|
35914639
detail...
|
NRAS exon3
|
colorectal cancer
|
resistant
|
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in metastatic colorectal cancer patients with NRAS exon 3 mutations (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
FLT3 exon17
|
acute myeloid leukemia
|
sensitive
|
Gilteritinib
|
Guideline |
Actionable |
Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
CD274 positive
|
gastroesophageal junction adenocarcinoma
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with advanced or metastatic gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274, CPS>=10) (PMID: 35914639; ESMO.org).
|
35914639
detail...
|
MSH6 negative
|
pancreatic cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second or later-line therapy for patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) pancreatic cancer (PMID: 37678671; ESMO.org).
|
detail...
37678671
|
CD274 positive
|
bladder urothelial carcinoma
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines for patients with CD274 (PD-L1)-positive advanced or metastatic bladder urothelial carcinoma who are not eligible for cisplatin-based chemotherapy (PMID: 34861372; ESMO.org).
|
34861372
detail...
|
KIT exon11
|
gastrointestinal stromal tumor
|
sensitive
|
Regorafenib
|
Guideline |
Actionable |
Stivarga (regorafenib) is included in guidelines as third-line or subsequent therapy for locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) patients harboring sensitizing mutations, such as KIT exon 11 mutations (PMID: 34560242; ESMO.org).
|
34560242
detail...
|
FGFR3 act mut
|
bladder urothelial carcinoma
|
sensitive
|
Erdafitinib
|
Guideline |
Actionable |
Balversa (erdafitinib) is included in guidelines for patients with advanced or metastatic bladder urothelial carcinoma harboring FGFR alterations (PMID: 34861372; ESMO.org).
|
detail...
34861372
|
CD274 positive
|
head and neck squamous cell carcinoma
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with CD274 (PD-L1)-positive (CPS >/=1) recurrent or metastatic head and neck squamous cell carcinoma (PMID: 34844180; ESMO.org).
|
detail...
34844180
|
MSH6 negative
|
endometrial cancer
|
sensitive
|
Avelumab
|
Guideline |
Actionable |
Bavencio (avelumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
35690222
detail...
|
FLT3 exon20
|
acute myeloid leukemia
|
sensitive
|
Cytarabine + Daunorubicin + Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines as first-line treatment for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
ALK rearrange
|
Cancer of Unknown Primary
|
sensitive
|
Alectinib
|
Guideline |
Actionable |
Alecensa (alectinib) is included in guidelines for patients with cancer of unknown primary harboring ALK rearrangements (PMID: 36563965, PMID: 30285222; ESMO.org).
|
detail...
30285222
36563965
|
MSH6 negative
|
endometrial cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
CD274 positive
|
esophagus squamous cell carcinoma
|
sensitive
|
Nivolumab
|
Guideline |
Actionable |
Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, TPS>=1%) (PMID: 35914638; ESMO.org).
|
detail...
35914638
|
FLT3 exon19
|
acute myeloid leukemia
|
sensitive
|
Cytarabine + Daunorubicin + Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines as first-line treatment for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
KIT exon11
|
gastrointestinal stromal tumor
|
sensitive
|
Imatinib
|
Guideline |
Actionable |
Gleevec (imatinib) is included in guidelines for gastrointestinal stromal tumor (GIST) patients harboring sensitizing mutations, such as KIT exon 11 mutations, as adjuvant therapy for patients with localized disease and as first-line therapy for patients with locally advanced, unresectable, or metastatic disease (PMID: 34560242; ESMO.org).
|
34560242
detail...
|
MSH6 negative
|
endometrial cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
detail...
35690222
|
MLH1 negative
|
endometrial cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
RET mutant
|
thyroid gland medullary carcinoma
|
sensitive
|
Selpercatinib
|
Guideline |
Actionable |
Retevmo (selpercatinib) is included in guidelines for adult or pediatric patients 12 years or older with advanced medullary thyroid gland carcinoma harboring RET mutations (PMID: 31549998, PMID: 35491008; ESMO.org).
|
31549998
detail...
35491008
|
MSH2 negative
|
endometrial cancer
|
sensitive
|
Avelumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Bavencio (avelumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
36696825
detail...
|
MSH2 negative
|
endometrial cancer
|
sensitive
|
Nivolumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
CD274 positive
|
bladder urothelial carcinoma
|
sensitive
|
Atezolizumab
|
Guideline |
Actionable |
Tecentriq (atezolizumab) is included in guidelines for patients with CD274 (PD-L1)-positive advanced or metastatic bladder urothelial carcinoma who are not eligible for cisplatin-based chemotherapy (PMID: 34861372; ESMO.org).
|
34861372
detail...
|
FLT3 exon 14 ins
|
acute myeloid leukemia
|
sensitive
|
Cytarabine + Daunorubicin + Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines as first-line treatment for patients with acute myeloid leukemia harboring FLT3 ITD mutations (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
ALK rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Alectinib
|
Guideline |
Actionable |
Alecensa (alectinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring an ALK rearrangement (PMID: 30285222; ESMO.org).
|
30285222
detail...
|
CD274 positive
|
head and neck squamous cell carcinoma
|
sensitive
|
Cisplatin + Fluorouracil + Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) in combination with platinum and Adrucil (fluorouracil) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with CD274 (PD-L1)-positive (CPS >/=1) recurrent or metastatic head and neck squamous cell carcinoma (PMID: 34844180; ESMO.org).
|
detail...
34844180
|
MSH6 negative
|
endometrial cancer
|
predicted - sensitive
|
Durvalumab
|
Guideline |
Actionable |
Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
detail...
35690222
|
BRAF V600E
|
colorectal cancer
|
sensitive
|
Cetuximab + Encorafenib
|
Guideline |
Actionable |
Braftovi (encorafenib) in combination with Erbitux (cetuximab) is included in guidelines as second-line or subsequent therapy for patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
BRAF V600X
|
lung non-small cell carcinoma
|
sensitive
|
Dabrafenib + Trametinib
|
Guideline |
Actionable |
The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring a BRAF V600 mutation, or as subsequent therapy in patients harboring BRAF V600 mutations that have not received prior BRAF/MEK inhibitor therapy (PMID: 30285222; ESMO.org).
|
detail...
30285222
|
KIT exon9
|
gastrointestinal stromal tumor
|
sensitive
|
Regorafenib
|
Guideline |
Actionable |
Stivarga (regorafenib) is included in guidelines as third-line or subsequent therapy for locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) patients harboring sensitizing mutations, such as KIT exon 9 mutations (PMID: 34560242; ESMO.org).
|
34560242
detail...
|
MSH2 negative
|
colorectal cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
ALK rearrange
|
Cancer of Unknown Primary
|
sensitive
|
Brigatinib
|
Guideline |
Actionable |
Alunbrig (brigatinib) is included in guidelines for patients with cancer of unknown primary harboring ALK rearrangements (PMID: 36563965, PMID: 30285222; ESMO.org).
|
30285222
detail...
36563965
|
TP53 mutant
|
chronic lymphocytic leukemia
|
sensitive
|
Acalabrutinib
|
Guideline |
Actionable |
Calquence (acalabrutinib) is included in the guidelines as first-line therapy for patients with advanced chronic lymphocytic leukemia harboring TP53 mutations and for patients with relapsed or refractory disease (PMID: 33091559; ESMO.org).
|
33091559
detail...
|
FLT3 exon17
|
acute myeloid leukemia
|
sensitive
|
Cytarabine + Daunorubicin + Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines as first-line treatment for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
MLH1 negative
|
endometrial cancer
|
sensitive
|
Durvalumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
36696825
detail...
|
MSH6 negative
|
colorectal cancer
|
sensitive
|
Ipilimumab + Nivolumab
|
Guideline |
Actionable |
Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as a second-line therapy for patients with advanced or metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) who progressed on first-line chemotherapy (PMID: 37236086; ESMO.org).
|
detail...
37236086
|
FLT3 exon20
|
acute myeloid leukemia
|
sensitive
|
Gilteritinib
|
Guideline |
Actionable |
Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
CD274 positive
|
stomach cancer
|
sensitive
|
Nivolumab
|
Guideline |
Actionable |
Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated gastric cancer expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org).
|
detail...
35914639
|
KIT exon11
|
gastrointestinal stromal tumor
|
sensitive
|
Sunitinib
|
Guideline |
Actionable |
Sutent (sunitinib) is included in guidelines as second-line or subsequent therapy for locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) patients harboring sensitizing mutations, such as KIT exon 11 mutations (PMID: 34560242; ESMO.org).
|
34560242
detail...
|
RET fusion
|
differentiated thyroid gland carcinoma
|
sensitive
|
Pralsetinib
|
Guideline |
Actionable |
Gavreto (pralsetinib) is included in guidelines for adult or pediatric patients 12 years or older with radioactive iodine-refractory, advanced or metastatic differentiated thyroid gland carcinoma harboring RET fusions (PMID: 31549998, PMID: 35491008; ESMO.org).
|
35491008
31549998
detail...
|
MLH1 negative
|
pancreatic cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second or later-line therapy for patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) pancreatic cancer (PMID: 37678671; ESMO.org).
|
37678671
detail...
|
MSH6 negative
|
endometrial cancer
|
sensitive
|
Atezolizumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Tecentriq (atezolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
PMS2 negative
|
endometrial cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
35690222
detail...
|
MLH1 negative
|
endometrial cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
35690222
detail...
|
MSH6 negative
|
stomach cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with advanced or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) gastric cancer (PMID: 35914639; ESMO.org).
|
35914639
detail...
|
BRAF V600X
|
skin melanoma
|
sensitive
|
Dabrafenib + Trametinib
|
Guideline |
Actionable |
BRAF inhibitor plus MEK inhibitor combination therapy, such as Tafinlar (dabrafenib) plus Mekinist (trametinib), is included in guidelines for cutaneous melanoma patients with unresectable or metastatic disease harboring a BRAF V600 mutation (PMID: 31566661; ESMO.org).
|
31566661
detail...
|
PMS2 negative
|
endometrial cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
NRAS mutant
|
thyroid gland medullary carcinoma
|
sensitive
|
Cabozantinib
|
Guideline |
Actionable |
Cometriq (cabozantinib) is included in guidelines for patients with advanced or metastatic medullary thyroid carcinoma harboring RAS mutations (PMID: 31549998, PMID: 35491008; ESMO.org).
|
35491008
31549998
detail...
|
NRAS exon3
|
colorectal cancer
|
resistant
|
Cetuximab
|
Guideline |
Actionable |
Erbitux (cetuximab) is not indicated for use in metastatic colorectal cancer patients with NRAS exon 3 mutations (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
FLT3 exon 15 ins
|
acute myeloid leukemia
|
sensitive
|
Cytarabine + Daunorubicin + Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines as first-line treatment fro for patients with acute myeloid leukemia harboring FLT3 ITD mutations (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
ALK rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Alectinib
|
Guideline |
Actionable |
Alecensa (alectinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for non-small cell lung cancer patients with ALK rearrangements, including patients with CNS involvement, and as subsequent therapy for patients that progress on Xalkori (crizotinib) (PMID: 30596843; ESMO.org).
|
30596843
detail...
|
KIT exon11
|
gastrointestinal stromal tumor
|
sensitive
|
Ripretinib
|
Guideline |
Actionable |
Qinlock (ripretinib) is included in guidelines as fourth-line or subsequent therapy for locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) patients harboring sensitizing mutations, such as KIT exon 11 mutations (PMID: 34560242; ESMO.org).
|
34560242
detail...
|
FLT3 exon 14 ins
|
acute myeloid leukemia
|
sensitive
|
Gilteritinib
|
Guideline |
Actionable |
Xospata (gilteritinib) is included in the guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation (PMID: 32171751; ESMO.org).
|
detail...
32171751
|
MLH1 negative
|
Cancer of Unknown Primary
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) cancer of unknown primary (CUP), or as first-line therapy for patients with MSI-H or dMMR colon-like CUP (PMID: 36563965; ESMO.org).
|
detail...
36563965
|
NRAS exon2
|
colorectal cancer
|
resistant
|
Cetuximab
|
Guideline |
Actionable |
Erbitux (cetuximab) is not indicated for use in metastatic colorectal cancer patients with NRAS exon 2 mutations (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
MSH2 negative
|
colorectal cancer
|
sensitive
|
Ipilimumab + Nivolumab
|
Guideline |
Actionable |
Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in guidelines as second-line therapy for patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
PMS2 negative
|
endometrial cancer
|
sensitive
|
Atezolizumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Tecentriq (atezolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
ALK rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Ensartinib
|
Guideline |
Actionable |
Ensartinib (X-396) is included in guidelines for patients with metastatic non-small cell lung cancer harboring an ALK rearrangement (PMID: 30285222, Version Update 15 Sept 2020; ESMO.org).
|
detail...
30285222
|
BRAF V600E
|
biliary tract cancer
|
sensitive
|
Dabrafenib + Trametinib
|
Guideline |
Actionable |
Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is included in guidelines as second or later-line therapy for patients with biliary tract cancer harboring BRAF V600E (PMID: 36372281; ESMO.org).
|
36372281
detail...
|
FGFR2 act mut
|
bladder urothelial carcinoma
|
sensitive
|
Erdafitinib
|
Guideline |
Actionable |
Balversa (erdafitinib) is included in guidelines for patients with advanced or metastatic bladder urothelial carcinoma harboring FGFR alterations (PMID: 34861372; ESMO.org).
|
detail...
34861372
|
MLH1 negative
|
colorectal cancer
|
sensitive
|
Ipilimumab + Nivolumab
|
Guideline |
Actionable |
Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in guidelines as second-line therapy for patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
PMS2 negative
|
colorectal cancer
|
sensitive
|
Ipilimumab + Nivolumab
|
Guideline |
Actionable |
Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as a second-line therapy for patients with advanced or metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) who progressed on first-line chemotherapy (PMID: 37236086; ESMO.org).
|
detail...
37236086
|
IDH1 mutant
|
cholangiocarcinoma
|
sensitive
|
Ivosidenib
|
Guideline |
Actionable |
Tibsovo (ivosidenib) is included in guidelines as second or later-line therapy for patients with cholangiocarcinoma harboring IDH1 mutations (PMID: 36372281; ESMO.org).
|
detail...
36372281
|
CD274 positive
|
triple-receptor negative breast cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
The combination of Keytruda (pembrolizumab) plus chemotherapy such as Taxol (paclitaxel), Abraxane (nab-paclitaxel), or Paraplatin (carboplatin) plus Gemzar (gemcitabine) is included in guidelines as first line therapy for CD274 (PD-L1)-positive patients with triple-negative breast cancer (PMID: 34678411; ESMO.org).
|
detail...
34678411
|
PMS2 negative
|
pancreatic cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second or later-line therapy for patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) pancreatic cancer (PMID: 37678671; ESMO.org).
|
37678671
detail...
|
FLT3 exon18
|
acute myeloid leukemia
|
sensitive
|
Cytarabine + Daunorubicin + Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines as first-line treatment for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
MSH2 negative
|
endometrial cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
35690222
detail...
|
MSH6 negative
|
endometrial cancer
|
sensitive
|
Avelumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Bavencio (avelumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
MSH6 negative
|
endometrial cancer
|
sensitive
|
Dostarlimab-gxly
|
Guideline |
Actionable |
Jemperli (dostarlimab-gxly) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
35690222
detail...
|
ROS1 rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Crizotinib
|
Guideline |
Actionable |
Xalkori (crizotinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring a ROS1 rearrangement, or as a next-line therapy in patients with ROS1-rearranged non-small cell lung cancer who have not received prior Xalkori (crizotinib) therapy (PMID: 30285222; ESMO.org).
|
detail...
30285222
|
RET M918T
|
thyroid gland medullary carcinoma
|
sensitive
|
Cabozantinib
|
Guideline |
Actionable |
Cometriq (cabozantinib) is included in guidelines for patients with advanced or metastatic medullary thyroid carcinoma harboring RET M918T (PMID: 31549998, PMID: 35491008; ESMO.org).
|
31549998
detail...
35491008
|
HRAS mutant
|
thyroid gland medullary carcinoma
|
sensitive
|
Cabozantinib
|
Guideline |
Actionable |
Cometriq (cabozantinib) is included in guidelines for patients with advanced or metastatic medullary thyroid carcinoma harboring RAS mutations (PMID: 31549998, PMID: 35491008; ESMO.org).
|
35491008
31549998
detail...
|
BRAF V600E
|
thyroid gland anaplastic carcinoma
|
sensitive
|
Dabrafenib + Trametinib
|
Guideline |
Actionable |
Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for patients with advanced or metastatic thyroid gland anaplastic carcinoma harboring BRAF V600E (PMID: 31549998, PMID: 35491008; ESMO.org).
|
31549998
detail...
35491008
|
BRAF V600X
|
skin melanoma
|
sensitive
|
Cobimetinib + Vemurafenib
|
Guideline |
Actionable |
BRAF inhibitor plus MEK inhibitor combination therapy, such as Cotellic (cobimetinib) plus Zelboraf (vemurafenib), is included in guidelines for cutaneous melanoma patients with unresectable or metastatic disease harboring a BRAF V600 mutation (PMID: 31566661; ESMO.org).
|
31566661
detail...
|
MLH1 negative
|
endometrial cancer
|
sensitive
|
Avelumab
|
Guideline |
Actionable |
Bavencio (avelumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
35690222
detail...
|
CD274 positive
|
triple-receptor negative breast cancer
|
sensitive
|
Atezolizumab + Nab-paclitaxel
|
Guideline |
Actionable |
The combination of Tecentriq (atezolizumab) and Abraxane (nab-paclitaxel) is included in guidelines as first line therapy for CD274 (PD-L1)-positive patients with triple-negative breast cancer (PMID: 34678411; ESMO.org).
|
34678411
detail...
|
FLT3 exon15
|
acute myeloid leukemia
|
sensitive
|
Cytarabine + Daunorubicin + Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines as first-line treatment for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
TP53 mutant
|
chronic lymphocytic leukemia
|
sensitive
|
Venetoclax
|
Guideline |
Actionable |
Venclexta (venetoclax) is included in the guidelines as first-line therapy for patients with advanced chronic lymphocytic leukemia harboring TP53 mutations and for patients with relapsed or refractory disease (PMID: 33091559; ESMO.org).
|
detail...
33091559
|
PMS2 negative
|
endometrial cancer
|
sensitive
|
Durvalumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
36696825
detail...
|
FLT3 exon15
|
acute myeloid leukemia
|
sensitive
|
Gilteritinib
|
Guideline |
Actionable |
Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
detail...
32171751
|
ROS1 rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Entrectinib
|
Guideline |
Actionable |
Rozlytrek (entrectinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring a ROS1 rearrangement, or as a next-line therapy in patients with ROS1-rearranged non-small cell lung cancer who have not received prior ROS1 inhibitor therapy (PMID: 30285222, Version Update 15 Sept 2020; ESMO.org).
|
30285222
detail...
|
MLH1 negative
|
endometrial cancer
|
sensitive
|
Durvalumab
|
Guideline |
Actionable |
Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
35690222
detail...
|
PMS2 negative
|
Cancer of Unknown Primary
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) cancer of unknown primary (CUP), or as first-line therapy for patients with MSI-H or dMMR colon-like CUP (PMID: 36563965; ESMO.org).
|
detail...
36563965
|
MLH1 negative
|
endometrial cancer
|
sensitive
|
Avelumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Bavencio (avelumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
36696825
detail...
|
MLH1 negative
|
colorectal cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with advanced or metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 37236086; ESMO.org).
|
detail...
37236086
|
MLH1 negative
|
endometrial cancer
|
sensitive
|
Atezolizumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Tecentriq (atezolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
TP53 mutant
|
chronic lymphocytic leukemia
|
sensitive
|
Obinutuzumab + Venetoclax
|
Guideline |
Actionable |
Venclexta (venetoclax) and Gazyva (obinutuzumab) combination therapy is included in the guidelines as first-line therapy for patients with advanced chronic lymphocytic leukemia harboring TP53 mutations and for patients with relapsed or refractory disease (PMID: 33091559; ESMO.org).
|
33091559
detail...
|
CD274 positive
|
esophagus squamous cell carcinoma
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, CPS>=10), and as second or subsequent lines of treatment for previously treated patients who have not received immunotherapy and with CPS>=10 (PMID: 35914638; ESMO.org).
|
detail...
35914638
|
ALK rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Brigatinib
|
Guideline |
Actionable |
Alunbrig (brigatinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring an ALK rearrangement (PMID: 30285222; ESMO.org).
|
detail...
30285222
|
PMS2 negative
|
endometrial cancer
|
sensitive
|
Dostarlimab-gxly
|
Guideline |
Actionable |
Jemperli (dostarlimab-gxly) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or advanced endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
36696825
detail...
|
FLT3 exon22
|
acute myeloid leukemia
|
sensitive
|
Cytarabine + Daunorubicin + Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines as first-line treatment for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
detail...
32171751
|
ROS1 rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Repotrectinib
|
Guideline |
Actionable |
Augtyro (repotrectinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring a ROS1 rearrangement, or as a next-line therapy in patients with ROS1-rearranged non-small cell lung cancer who have not received prior ROS1 inhibitor therapy (PMID: 30285222, Version Update 15 Sept 2020; ESMO.org).
|
detail...
30285222
|
ALK rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Ceritinib
|
Guideline |
Actionable |
Zykadia (ceritinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for non-small cell lung cancer patients with ALK rearrangements, including patients with CNS involvement, and as subsequent therapy for patients that progress on Xalkori (crizotinib) (PMID: 30596843; ESMO.org).
|
detail...
30596843
|
ROS1 rearrange
|
Cancer of Unknown Primary
|
sensitive
|
Crizotinib
|
Guideline |
Actionable |
Xalkori (crizotinib) is included in guidelines for patients with cancer of unknown primary harboring ROS1 rearrangements (PMID: 36563965, PMID: 30285222; ESMO.org).
|
detail...
30285222
36563965
|
NRAS exon4
|
colorectal cancer
|
resistant
|
Cetuximab
|
Guideline |
Actionable |
Erbitux (cetuximab) is not indicated for use in metastatic colorectal cancer patients with NRAS exon 4 mutations (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
MLH1 negative
|
stomach cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with advanced or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) gastric cancer (PMID: 35914639; ESMO.org).
|
35914639
detail...
|
ROS1 rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Lorlatinib
|
Guideline |
Actionable |
Lorbrena (lorlatinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring a ROS1 rearrangement, or as a next-line therapy in patients with ROS1-rearranged non-small cell lung cancer who have not received prior ROS1 inhibitor therapy (PMID: 30285222, Version Update 15 Sept 2020; ESMO.org).
|
30285222
detail...
|
MSH2 negative
|
Cancer of Unknown Primary
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) cancer of unknown primary (CUP), or as first-line therapy for patients with MSI-H or dMMR colon-like CUP (PMID: 36563965; ESMO.org).
|
detail...
36563965
|
PMS2 negative
|
endometrial cancer
|
sensitive
|
Dostarlimab-gxly
|
Guideline |
Actionable |
Jemperli (dostarlimab-gxly) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
35690222
detail...
|
MSH2 negative
|
pancreatic cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second or later-line therapy for patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) pancreatic cancer (PMID: 37678671; ESMO.org).
|
detail...
37678671
|
PMS2 negative
|
colorectal cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
MSH6 negative
|
endometrial cancer
|
sensitive
|
Nivolumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
FGFR2 fusion
|
cholangiocarcinoma
|
sensitive
|
Pemigatinib
|
Guideline |
Actionable |
Pemazyre (pemigatinib) is included in guidelines as second or later-line therapy for patients with cholangiocarcinoma harboring FGFR2 fusions (PMID: 36372281; ESMO.org).
|
36372281
detail...
|
FGFR3 fusion
|
bladder urothelial carcinoma
|
sensitive
|
Erdafitinib
|
Guideline |
Actionable |
Balversa (erdafitinib) is included in guidelines for patients with advanced or metastatic bladder urothelial carcinoma harboring FGFR alterations (PMID: 34861372; ESMO.org).
|
detail...
34861372
|
PMS2 negative
|
colorectal cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with advanced or metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 37236086; ESMO.org).
|
detail...
37236086
|
FLT3 exon23
|
acute myeloid leukemia
|
sensitive
|
Gilteritinib
|
Guideline |
Actionable |
Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
KIT exon9
|
gastrointestinal stromal tumor
|
sensitive
|
Imatinib
|
Guideline |
Actionable |
Gleevec (imatinib) is included in guidelines for gastrointestinal stromal tumor (GIST) patients harboring sensitizing mutations, such as KIT exon 9 mutations, as adjuvant therapy for patients with localized disease and as first-line therapy for patients with locally advanced, unresectable, or metastatic disease (PMID: 34560242; ESMO.org).
|
34560242
detail...
|
BRAF V600E
|
colorectal cancer
|
resistant
|
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab), as a monotherapy, is not indicated for use in metastatic colorectal cancer patients with BRAF V600E (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
MSH2 negative
|
endometrial cancer
|
sensitive
|
Dostarlimab-gxly
|
Guideline |
Actionable |
Jemperli (dostarlimab-gxly) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
35690222
detail...
|
MSH6 negative
|
cholangiocarcinoma
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second or late-line therapy for patients with cholangiocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36372281; ESMO.org).
|
detail...
36372281
|
MSH2 negative
|
endometrial cancer
|
sensitive
|
Atezolizumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Tecentriq (atezolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
MSH2 negative
|
colorectal cancer
|
sensitive
|
Ipilimumab + Nivolumab
|
Guideline |
Actionable |
Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as a second-line therapy for patients with advanced or metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) who progressed on first-line chemotherapy (PMID: 37236086; ESMO.org).
|
detail...
37236086
|
ALK rearrange
|
Cancer of Unknown Primary
|
sensitive
|
Ceritinib
|
Guideline |
Actionable |
Zykadia (ceritinib) is included in guidelines for patients with cancer of unknown primary harboring ALK rearrangements (PMID: 36563965, PMID: 30285222; ESMO.org).
|
detail...
30285222
36563965
|
FLT3 exon23
|
acute myeloid leukemia
|
sensitive
|
Cytarabine + Daunorubicin + Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines as first-line treatment for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
detail...
32171751
|
ALK rearrange
|
Cancer of Unknown Primary
|
sensitive
|
Crizotinib
|
Guideline |
Actionable |
Xalkori (crizotinib) is included in guidelines for patients with cancer of unknown primary harboring ALK rearrangements (PMID: 36563965, PMID: 30285222; ESMO.org).
|
detail...
30285222
36563965
|
NRAS exon4
|
colorectal cancer
|
resistant
|
Panitumumab
|
Guideline |
Actionable |
Vectibix (panitumumab) is not indicated for use in metastatic colorectal cancer patients with NRAS exon 4 mutations (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
MSH6 negative
|
colorectal cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
CD274 positive
|
esophageal cancer
|
sensitive
|
Nivolumab
|
Guideline |
Actionable |
Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated esophageal cancer expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org).
|
35914639
detail...
|
MLH1 negative
|
colorectal cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36307056; ESMO.org).
|
36307056
detail...
|
FGFR2 fusion
|
cholangiocarcinoma
|
sensitive
|
Infigratinib
|
Guideline |
Actionable |
Truseltiq (infigratinib) is included in guidelines as second or later-line therapy for patients with cholangiocarcinoma harboring FGFR2 fusions (PMID: 36372281; ESMO.org).
|
36372281
detail...
|
ALK rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Lorlatinib
|
Guideline |
Actionable |
Lorbrena (lorlatinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) as subsequent therapy for patients who have progressed on second-generation ALK inhibitors (PMID: 30596843; ESMO.org).
|
30596843
detail...
|
MSH6 negative
|
endometrial cancer
|
predicted - sensitive
|
Durvalumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
36696825
detail...
|
MSH2 negative
|
endometrial cancer
|
sensitive
|
Durvalumab
|
Guideline |
Actionable |
Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
detail...
35690222
|
FLT3 exon18
|
acute myeloid leukemia
|
sensitive
|
Gilteritinib
|
Guideline |
Actionable |
Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
MLH1 negative
|
endometrial cancer
|
sensitive
|
Nivolumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
ALK rearrange
|
lung non-small cell carcinoma
|
sensitive
|
Crizotinib
|
Guideline |
Actionable |
Xalkori (crizotinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for non-small cell lung cancer patients with ALK rearrangements (PMID: 30596843; ESMO.org).
|
detail...
30596843
|
PMS2 negative
|
endometrial cancer
|
sensitive
|
Avelumab
|
Guideline |
Actionable |
Bavencio (avelumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org).
|
detail...
35690222
|
MSH2 negative
|
colorectal cancer
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with advanced or metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 37236086; ESMO.org).
|
detail...
37236086
|
RET fusion
|
differentiated thyroid gland carcinoma
|
sensitive
|
Selpercatinib
|
Guideline |
Actionable |
Retevmo (selpercatinib) is included in guidelines for patients with advanced or metastatic differentiated thyroid gland carcinoma harboring RET fusions (PMID: 31549998, PMID: 35491008; ESMO.org).
|
35491008
31549998
detail...
|
FLT3 exon 15 ins
|
acute myeloid leukemia
|
sensitive
|
Gilteritinib
|
Guideline |
Actionable |
Xospata (gilteritinib) is included in the guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
FLT3 exon21
|
acute myeloid leukemia
|
sensitive
|
Gilteritinib
|
Guideline |
Actionable |
Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
PMS2 negative
|
endometrial cancer
|
sensitive
|
Nivolumab
|
Guideline |
Actionable |
Immune checkpoint inhibitor monotherapy including Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
detail...
36696825
|
MLH1 negative
|
endometrial cancer
|
sensitive
|
Dostarlimab-gxly
|
Guideline |
Actionable |
Jemperli (dostarlimab-gxly) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or advanced endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org).
|
36696825
detail...
|
MLH1 negative
|
cholangiocarcinoma
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second or late-line therapy for patients with cholangiocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36372281; ESMO.org).
|
36372281
detail...
|
MSH6 negative
|
Cancer of Unknown Primary
|
sensitive
|
Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) cancer of unknown primary (CUP), or as first-line therapy for patients with MSI-H or dMMR colon-like CUP (PMID: 36563965; ESMO.org).
|
detail...
36563965
|
MLH1 negative
|
colorectal cancer
|
sensitive
|
Ipilimumab + Nivolumab
|
Guideline |
Actionable |
Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as a second-line therapy for patients with advanced or metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) who progressed on first-line chemotherapy (PMID: 37236086; ESMO.org).
|
37236086
detail...
|
FLT3 exon14
|
acute myeloid leukemia
|
sensitive
|
Cytarabine + Daunorubicin + Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines as first-line treatment for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (PMID: 32171751; ESMO.org).
|
32171751
detail...
|
CD274 positive
|
head and neck squamous cell carcinoma
|
sensitive
|
Carboplatin + Fluorouracil + Pembrolizumab
|
Guideline |
Actionable |
Keytruda (pembrolizumab) in combination with platinum and Adrucil (fluorouracil) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with CD274 (PD-L1)-positive (CPS >/=1) recurrent or metastatic head and neck squamous cell carcinoma (PMID: 34844180; ESMO.org).
|
34844180
detail...
|